日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

BIZCHINA> Top Biz News
Profits up for flu vaccine makers
By Ding Qingfen (China Daily)
Updated: 2009-11-16 07:55

Profits up for flu vaccine makers

Primary school students receive injections of anti-H1N1 influenza medicine in Hunan province. GlaxoSmithKline (GSK) has received orders for 1.2 million packs of its anti-H1N1 influenza medicine, Relenza, from the Chinese government. [Asianewsphoto]

International pharmaceutical companies are cashing in on China's efforts to protect its people from the H1N1 pandemic with anti-influenza medicines.

GlaxoSmithKline (GSK), a leading international pharmaceutical company and China's largest by sales volume, received approval from the State Food and Drug Administration for its anti-H1N1 influenza medicine to enter the China market in July.

Since then, GSK has prepared 1.2 million packs of the anti-H1N1 influenza medicine called Relenza available for governments at all levels in China. The governments are storing the anti-virus in anticipation of a massive flu outbreak in coming months.

"GSK expects very strong demand for Relenza this year in China," Mark Reilly, general manager of GSK China, told China Business Weekly.

Profits up for flu vaccine makers

Chen Zhaorong, area medical manager at GSK China, also predicted that GSK will receive more orders in the months ahead.

"Compared with that from the other nations worldwide, China's orders are still small (for GSK)," Chen said.

Actually, the production capacity for Relenza is around 60 million packs. GSK has contracts in place to supply Relenza to over 60 economies. Of which, at least 10 percent of its new production have been allocated for developing nations.

But Chinese rules require that only governments can purchase the anti-H1N1 flu medicine. Relenza is still unavailable for sale to consumers.

As the weather turns colder, China is now bracing for a major H1N1 flu case outbreak. As of Nov 11, more than 62,871 cases were reported in 31 provinces, municipalities and autonomous regions of the Chinese mainland. About 32,000 cases were reported just since Oct 12.

Related readings:
Profits up for flu vaccine makers 8M+ Chinese inoculated with A(H1N1) flu vaccine
Profits up for flu vaccine makers Two died after inoculation of A(H1N1) flu vaccine
Profits up for flu vaccine makers Beijing to extend A(H1N1) flu vaccine inoculation
Profits up for flu vaccine makers H1N1 vaccine and common flu vaccine to merge

"Many regions are entering the traditional period for possible flu outbreaks, which will last for two to three months, and prevention and control work is becoming tougher," said Liang Wannian, vice director of the health emergency office under the Ministry of Health.

The Chinese government plans to allocate 1.09 billion yuan ($159.65 million) for prevention and treatment of the flu, including purchases of vaccinations, anti-viral medicines and medical instruments.

The huge investment is attracting global players like GSK. To meet the growing demand for anti-virals in China, GSK is considering investing in a manufacturing facility to produce Relenza for the country, said the GSK's Reilly, declining to elaborate.


(For more biz stories, please visit Industries)

   Previous page 1 2 Next Page  

主站蜘蛛池模板: 午夜视频导航 | 精品中出 | 中文字幕高清 | 麻豆av在线播放 | 最新国产精品 | 男人午夜天堂 | 男人天堂网av| wwwwww国产 | 97毛片 | 精品一区二区三区视频 | 精品在线免费观看 | 四虎黄色片 | 亚洲五码av | 男女插插插视频 | 久久久夜夜夜 | 欧美精品久久久久久 | 三级国产在线观看 | 午夜精品福利一区二区 | 影音先锋国产在线 | 中文字幕免费看 | 日韩在线观看网址 | 99精品欧美一区二区蜜桃免费 | 精品一区二区三区三区 | 亚洲成人a v| 一级免费黄色录像 | 超碰伊人久久 | 免费在线观看一区二区 | 一级片免费在线观看 | 久久久久无码国产精品一区 | 99精品国产一区二区 | 在线你懂的 | 久久大胆视频 | 自拍偷拍欧美亚洲 | 午夜视频1000| 欧美亚洲大片 | 国产精品69久久久久孕妇欧美 | 欧美一区视频 | 中文字幕精品视频在线观看 | av中文字幕一区 | 天天操国产 | 狠狠干一区|